Suviray 70mg Injection: Effective Medication for Your Health

Active component: Erenumab

Class of medicines: Monoclonal antibodies

Uses:

• Prevention of migraine in adults

Mechanism of action:

• Suviray 70 mg Injection works by targeting and inhibiting the calcitonin gene-related peptide (CGRP) receptor. This affects the signaling pathway responsible for sending pain signals and dilation of blood vessels, both of which contribute to the development of migraines.

Administration:

• Suviray 70 mg Injection is administered as a subcutaneous injection. It is injected under the skin, typically in the abdomen or thigh area, once a month.

Safety advice:

• Do not use if you are allergic to the active compound Erenumab or its compounds.
• Discuss hypersensitivity reactions to biologic agents or other injectable treatments with your healthcare provider before starting Suviray 70 mg Injection.
• Not recommended for children and adolescents under 18 years old.
• Close monitoring required for elderly individuals.
• Dosage adjustments or careful monitoring may be necessary for individuals with severe liver or kidney impairment.
• Individuals with severe cardiovascular illnesses, such as uncontrolled hypertension or a history of heart attack, may need to monitor or change their treatment plan while using this medicine.
• Pregnant women and nursing mothers should consult their healthcare provider prior to taking Suviray 70 mg Injection.
• Inform your healthcare provider about all the medicines you are taking, including herbal, vitamin supplements, and over-the-counter medicines, before starting the treatment.

Storage:

• Store Suviray 70 mg Injection at room temperature (20°C to 25°C).
• Keep out of reach from children.
• Keep away from moisture, heat, and light.
• Do not freeze.

Side effects:

• Common: constipation, itching, vomiting, fatigue, nausea, muscle spasms, injection site reactions.
• Serious: serious allergic reactions, chronic constipation.

Word of advice:

• Be cautious with overuse of pain-relieving medications.
• Do not skip meals for a longer time.
• Eat foods rich in magnesium, omega-3 fatty acids, and hydrating foods.
• Use a migraine journal or smartphone app to record your migraine episodes.
• Maintain quality sleep around 7-9 hours and proper hydration with 8-10 glasses of water per day.

FAQs:

1. How long does Suviray 70 mg injection treatment last?

• Suviray 70 mg injection is typically administered as a monthly injection. Your healthcare provider will determine the appropriate duration of treatment based on your response and needs.

2. Who should receive treatment with Suviray 70 mg Injection?

• Adults who have four or more migraine days a month and have not responded well to or tolerated other preventative drugs may find Suviray 70 mg Injection to be a good option. To find out if Suviray 70 mg Injection is right for you, it's crucial to talk to your doctor about your migraine history and available treatments.

3. Can Suviray 70 mg injection cause weight gain?

• Weight gain is not a commonly reported side effect of Suviray 70 mg injection. However, individual responses to medications can vary. Consult your healthcare provider if you have concerns.

4. Is Suviray 70 mg injection suitable for all types of migraines?

• Suviray 70 mg injection is primarily indicated for the prevention of migraine attacks. Your healthcare provider will assess the type and frequency of your migraines to determine if Suviray 70 mg injection is appropriate for you.

5. What are Suviray 70 mg Injection's typical side effects?

• Constipation, muscle cramps, and injection site reactions (such as redness, discomfort, and swelling) are common Suviray 70 mg Injection side effects. Although uncommon, serious allergic reactions can occur. Notifying your healthcare provider of any adverse effects as soon as possible is crucial.

6. Can side effects worsen with higher Suviray 70 mg injection doses?

• Higher doses of Suviray 70 mg injection are not typically associated with worsened side effects. Your healthcare provider will determine the appropriate dose based on your condition.

Fact box:

• Molecule name: Erenumab
• Therapeutic class: Migraine prevention agent
• Pharmacological class: Calcitonin gene-related peptide (CGRP) receptor antagonist
• Indications: Prevention of migraine in adults
• Dosage form: Injection
• Habit forming: No

Tags: Suviray, Injection, Medical, Drugs, Medicine, Pharmaceuticals, HealthCare